María José Crespo Carballés

María José Crespo Carballés

Auto-generated profile, based on publicly available information

María José Crespo Carballés

Opthalmology Service, Hospital Universitario Infanta Leonor, 28031 Madrid, Spain

Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 January 2026 in Sensors
Verified
Journal Article
Open access
PDF file
MMMaría Moreno-Guzmán
María Moreno-Guzmán
Juan Pablo Pablo Hervás-PérezJuan Pablo Pablo Hervás-Pérez
Juan Pablo Pablo Hervás-Pérez
LMLaura Martín-Carbajo
Laura Martín-Carbajo
MCMaría José Crespo Carballés
María José Crespo Carballés
MLMarta Sánchez-Paniagua López
Marta Sánchez-Paniagua López
Glaucoma is a leading cause of irreversible blindness worldwide, with its asymptomatic progression highlighting the urgent need for early, minimally invasive biomarkers. Exosomes derived from the aqueous humor (AH) have emerged as promising candidates, as they carry proteins, nucleic acids, and lipids that reflect the physiological and pathological state of ocular tissues such as the trabecular meshwork and ciliary body. However, their low abundance, nanoscale size, and the limited volume of AH complicate detection and characterization. Conventional methods, including Western blotting, PCR or mass spectrometry, are labor-intensive, time-consuming, and often incompatible with microliter-scale samples. Electrochemical biosensors offer a highly sensitive, rapid, and low-volume alternative, enabling the detection of exosomal surface markers and internal cargos such as microRNAs, proteins, and lipids. Recent advances in nanomaterial-enhanced electrodes, microfluidic integration, enzyme- and nanozyme-mediated signal amplification, and ratiometric detection strategies have significantly improved sensitivity, selectivity, and multiplexing capabilities. While most studies focus on blood or serum, these platforms hold great potential for AH-derived exosome analysis, supporting early-stage glaucoma diagnosis, monitoring of disease progression, and evaluation of therapeutic responses. Continued development of miniaturized, point-of-care electrochemical biosensors could facilitate clinically viable, noninvasive exosome-based diagnostics for glaucoma.